Teva Pharmaceutical Industries and other generic-drug makers criticized the health care reform bill unveiled by Sen. Max Baucus, D-Mont., which would require such firms to pay the government higher rebates for medicines used in Medicaid. The proposal "could have the unintended consequence of also increasing the costs of generics for consumers and the government" by hampering competition, according to the Generic Pharmaceutical Association.

Full Story:

Related Summaries